MTOR and renal cell carcinoma: This led rapamycin and related mTOR inhibitors (like everolimus and temsirolimus) to be repurposed for cancer therapy, particularly where mTOR is highly active, such as renal cell carcinoma and certain types of breast and neuroendocrine tumours (Dancey 2010).